{
  "id": 3615380,
  "title": "Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet",
  "url": "https://urgent.news/2026/08/26/why-wall-street-sees-a-39-800-pancreatic-cancer-pill-as-proof-of-a",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T22:33:39.000Z",
  "source": {
    "name": "Fortune",
    "slug": "fortune",
    "url": "https://fortune.com/2026/08/26/pancreatic-cancer-fda-approval-pill-doubles-survival-rate-revolution-medicines/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Dr. Danish Nagda, a shareholder in the developer, told Fortune it was \"incredibly exciting ... maybe half a decade away from the post-cancer era.\"",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}